GlassScriptPhysician profile
Natalie R Dunn
NPI 1194446146
$2,203.88
in general payments reported to CMS, 2019-2025
28 companies · $1,084 in 2025
The $1,084 reported for 2025 was more than what 82% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $33.11 · 2023: $396 · 2024: $691 · 2025: $1,084.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,170.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $598.73 | 2024-2025 | |
| Sk Life Science, INC. | $343.02 | 2023-2024 | |
| Lilly USA, LLC | $155.83 | 2023-2025 | Amyvid, Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $117.82 | 2024-2025 | Rexulti |
| Pfizer INC. | $117.47 | 2023-2025 | |
| Novo Nordisk INC | $77.45 | 2025 | Wegovy, Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $74.59 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $64.04 | 2025 | Camzyos, Eliquis |
| Lundbeck LLC | $63.39 | 2024-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $62.91 | 2024-2025 | Caplyta |
| Alexion Pharmaceuticals, INC. | $60.20 | 2023-2024 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $54.58 | 2024-2025 | Airsupra |
| Exact Sciences Corporation | $48.92 | 2024-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $46.88 | 2024-2025 | Trelegy Ellipta, Bexsero |
| Ucb, INC. | $46.44 | 2023 | Briviact |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $36.14 | 2025 | Arikayce, Brinsupri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.30 | 2025 | Xifaxan |
| Astellas Pharma US INC | $25.50 | 2025 | Veozah |
| Mylan Specialty L.P. | $21.66 | 2024 | Yupelri |
| Biogen, INC. | $20.97 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $20.09 | 2023 | Austedo |
| Janssen Pharmaceuticals, INC | $19.29 | 2024 | Spravato |
| Viatris Specialty LLC | $18.01 | 2025 | Yupelri |
| Medtronic, INC. | $17.52 | 2023 | Linq II |
| Phathom Pharmaceuticals, INC. | $16.70 | 2025 | Voquezna |
| Axsome Therapeutics, INC. | $15.00 | 2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.29 | 2024 | Jardiance |
| Collegium Pharmaceutical, INC. | $12.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Dunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.